DOCSLIB.ORG

ANNUAL REPORT 2010 Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2010 Contents ANNUAL REPORT 2010 Contents I. Overviews ...............................................................................................................3 Year 2010 in review, Director of FIMM ............................................................................. 3 Views from the former and current Chair of the Board ...................................................5 II. FIMM Launch Event ................................................................................................ 6 III. How is the Nordic EMBL Partnership build-up progressing in Oslo and Umeå? ..........7 IV. Academician of Science, Professor Leena Peltonen-Palotie in memoriam .............. 8 V. Research ................................................................................................................ 10 Human Genomics ..........................................................................................................10 Medical Systems Biology and Translational Research ..................................................... 14 Research collaborations and highlights ..........................................................................21 Personalized medicine of cancer becoming a reality.......................................................25 Doctoral Training ...........................................................................................................26 VI. Technology Centre .................................................................................................28 Genomics Unit ..............................................................................................................28 Sequencing Unit ............................................................................................................29 Metabolomics Unit .......................................................................................................30 RNAi Unit ...................................................................................................................... 31 Chemical Biology Unit ...................................................................................................32 Bioinformatics, Data Management and IT-support Unit .................................................33 VII. Biobank .................................................................................................................35 National and International Infrastructure Projects .........................................................37 VIII. Administration Unit, Board and Scientific Advisory Board (SAB) ...........................39 IX. Selected Events in 2010 ......................................................................................... 41 X. FIMM in Figures ....................................................................................................44 Financial Report ...........................................................................................................44 Personnel Statistics .......................................................................................................45 XI. Publications by FIMM researchers 2010 .................................................................48 Publications by FIMM Molecular Medicine Network and adjunct researchers 2010 ........62 I. Overviews Year 2010 in review, Director of FIMM ramatic research progress is now being made in launched with funding from Biocenter Finland and a pi- Dhuman genomics, bioinformatics, systems biology lot project to support the build-up of international ESFRI and many other fields of biomedical research. The need infrastructure programmes. Almost half of FIMM’s activi- to bring breakthroughs in science to the everyday prac- ties (measured both in terms of funding and personnel) tice of medicine remains one of mankind’s biggest chal- are now focussed on infrastructure. FIMM is a prominent lenges. The mission of FIMM is to build a bridge from national and international infrastructure provider, help- discovery to medicine. The foundations for building ing a large community of researchers to do better sci- translational molecular medicine in Finland are excel- ence and facilitate translational medicine. lent. Finland has both a strong scientific base in biomed- ical research, but also excellent clinical and epidemiolog- The year 2010 started with dramatic news of the death ical research and a high-quality equal-access healthcare of the Academician of Science, Professor Leena Peltonen- infrastructure. However, unless these major advantages Palotie. Leena’s death was a deep loss to all of us at are brought together by multidisciplinary research col- FIMM as well as to the international human genomics laborations, we will not realize our full potential. This is community. Leena’s key impact in building the scientific what FIMM and the Nordic EMBL Partnership for Molec- foundation of FIMM is felt today and it will continue well ular Medicine are all about, realizing the full potential of after her death. In May 2011, we will organize a major small countries in Northern Europe to advance transla- international symposium to celebrate Leena’s lifetime tional molecular medicine by multidisciplinary collabo- achievements in genomics. rations with national and international networks. In March 2010, FIMM celebrated its official inauguration The year 2010 marked the third year in the build-up of ceremony followed by a scientific symposium. FIMM is FIMM as an international research institute. The year therefore now officially up and running and we can turn was characterized by rapid growth, exciting research the focus towards making progress in molecular med- progress, the setup of major national and international icine. Indeed, significant research progress has already research infrastructures and the launch of new biobank- been made, as demonstrated by the 90 publications by ing operations in the Meilahti Campus. By combining FIMM researchers, of which 21 were in top journals with first class molecular medicine research, state-of-the-art an impact factor >20. Many of the top publications repre- technology capabilities and access to large biobanks sent major international consortium studies on human and clinical data, we can build major translational op- genetics, largely initiated by the late Professor Leena Pel- portunities. This vision is behind the new organization tonen-Palotie, and now continued by the group leaders structure of FIMM, which is planned to take effect in at FIMM and at THL. In the area of human genomics, the 2011 (Figure 1). The primary focus of FIMM in translating role of FIMM group leaders has been leading in uncover- molecular medicine to clinical practice is via advancing ing e.g. the genetic basis of migraine and cardiovascu- personalized medicine, which is an area where we hope lar disease and the genetic origins of Finnish people. In to be able to also soon help patients and contribute to other areas, FIMM researchers published the first tran- the health of societies. scriptomic sequencing paper about breast cancer, set up a new personalized medicine profiling of cancer and car- During the year 2010, the number of employees at FIMM ried out many other key observations. In addition to the grew from 99 to 125, and the staff now represents 20 na- 90 publications by FIMM researchers, members of the tionalities. There are 13 group leaders at FIMM, all ap- FIMM National Network for Molecular Medicine and ad- pointed based on international evaluation. Half of the junct researchers published another 43 publications. group leaders are EMBL-style principal investigators and two are established Finland Distinguished Professors. In FIMM researchers have also been very successful in se- 2010, the build-up of new infrastructures at FIMM was curing external competitive research funding, such as FIMM 3 new projects from the EU and the IMI (Innovative Medi- land (please see below) put an overwhelmingly strong cines Initiative), a joint EU – Pharma collaborative pro- emphasis on improving the international profile of Finn- gramme. External funding now amounts to >50% of the ish science. This is seen as a key aspect of helping Fin- total FIMM budget, with a further increase predicted land stay competitive in the global competition for sci- in this percentage in 2011—2012. Acquiring, reporting ence and innovation. We have seen tremendously rapid and managing a project portfolio of some 30 individual progress at FIMM, which can to a large extent be cred- grants at FIMM in 2010 is starting to be a significant ad- ited to its international profile and strong networks, the ministrative challenge. While the increased external sup- brand of the EMBL partnership as well as the strategic port is overwhelmingly positive, there are also many as- international recruitment of talent to Finland. Thus, we pects of an international EMBL-associated institute that hope that FIMM will continue to prosper by building up- cannot be run only based on short-term competitive on these strengths. funding. Recruitment of international, talented principal investigators will continue to require a strong institu- Professor Olli Kallioniemi, Director, FIMM tional funding base. In the first five years, private foun- dations have done a remarkable job in helping to sup- Research and innovation policy guidelines for 2011–2015; port this aspect of FIMM operations. We hope to work research and Innovation Council with the partners and supporters of FIMM to maintain a strong basic funding also in the future when the first five Research Policy:
Load more

Recommended publications
  • IST Annual Report 2019
    Annual Report 2019 IST Austria administrative and The people of IST Austria technical support staff by nationality Austria 59.4% Nationalities on campus Germany 5.6% Hungary 3.1% Poland 2.5% Romania 2.5% Scientists as well as administrative and technical support staff come Italy 2.1% Russia 1.7% from all over the world to conduct and back research at IST Austria. Czech Republic 1.4% As of December 31, 2019, a total of 72 nationalities were represented India 1.4% Slovakia 1.4% on campus. Spain 1.4% UK 1.4% Other 16.1% North America Europe Asia Canada Albania Italy Afghanistan Cuba Andorra Latvia Bangladesh El Salvador Armenia Lithuania China Mexico Austria Luxembourg South Korea USA Belarus Macedonia India Belgium Malta Iran Bosnia and Netherlands Israel Herzegovina Norway Japan Bulgaria Poland Jordan Croatia Portugal Kazakhstan Cyprus Romania Lebanon Czech Republic Serbia Mongolia Denmark Slovakia Philippines Finland Slovenia Russia France Spain Singapore Georgia Sweden Syria Germany Switzerland Vietnam Greece Turkey Hungary UK Ireland Ukraine Africa Egypt Kenya IST Austria scientists by nationality Libya Austria 14.7% Nigeria Germany 10.9% South America Italy 7.4% Argentina India 5.9% Russia 4.7% Brazil Slovakia 4.1% Chile China 4.1% Colombia Hungary 3.7% Peru Spain 3.3% Uruguay USA 3.1% Czech Republic 2.9% UK 2.4% Oceania Other 32.8% Australia Content 2 HAPPY BIRTHDAY! 40 RESEARCH 4 Foreword by the president 42 Biology 5 Board member voices 44 Computer science 6 “An Austrian miracle” 46 Mathematics A year of celebration 48 Neuroscience
    [Show full text]
  • A Role for the M9 Transport Signal of Hnrnp A1 in Mrna Nuclear Export Elisa Izaurralde,* Artur Jarmolowski,* Christina Beisel,* Iain W
    A Role for the M9 Transport Signal of hnRNP A1 in mRNA Nuclear Export Elisa Izaurralde,* Artur Jarmolowski,* Christina Beisel,* Iain W. Mattaj,* Gideon Dreyfuss,‡ and Utz Fischer‡ *European Molecular Biology Laboratory, D-69117 Heidelberg, Germany; and ‡Howard Hughes Medical Institute and Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Pennsylvania 19104-6148 Abstract. Among the nuclear proteins associated with snRNPs or proteins carrying a classical basic NLS. Pre- mRNAs before their export to the cytoplasm are the vious work demonstrated the existence of nuclear ex- abundant heterogeneous nuclear (hn) RNPs. Several of port factors specific for particular classes of RNA. In- these contain the M9 signal that, in the case of hnRNP jection of hnRNP A1 but not of a mutant protein A1, has been shown to be sufficient to signal both nu- lacking the M9 domain inhibited export of mRNA but clear export and nuclear import in cultured somatic not of other classes of RNA. This suggests that hnRNP cells. Kinetic competition experiments are used here to A1 or other proteins containing an M9 domain play a demonstrate that M9-directed nuclear import in Xeno- role in mRNA export from the nucleus. However, the pus oocytes is a saturable process. Saturating levels of requirement for M9 function in mRNA export is not M9 have, however, no effect on the import of either U identical to that in hnRNP A1 protein transport. he transport of macromolecules between the nu- function named variously pp15, p10, or NTF2 (Moore and cleus and cytoplasm is a bi-directional process.
    [Show full text]
  • Research at a Glance 2012
    European Molecular Biology Laboratory Research at a Glance 2012 European Molecular Biology Laboratory Research at a Glance 2012 www.embl.org Research at a Glance 2012 Contents Introduction 6 About EMBL 8 Career opportunities 10 EMBL Heidelberg, Germany Directors’ Research 12 Cell Biology and Biophysics Unit 18 Developmental Biology Unit 32 Genome Biology Unit 42 Structural and Computational Biology Unit 52 Core Facilities 66 EMBL-EBI, Hinxton, United Kingdom European Bioinformatics Institute 76 Bioinformatics Services 90 EMBL Grenoble, France Structural Biology 98 EMBL Hamburg, Germany Structural Biology 110 EMBL Monterotondo, Italy Mouse Biology 120 Index 130 | Research at a Glance 2012 | 5 “EMBL combines a critical mass of expertise and resources with organisational exibility, enabling us to keep pace with today’s biology.” – Iain Mattaj 6 | Research at a Glance 2012 | e vision of the nations which founded the European Molecular Biology Laboratory was to create a centre of excellence where Europe’s best brains would come together to conduct basic research in molecular biology and related elds. During the intervening decades, EMBL has grown and developed substantially, and its member states now number twenty-one, including the rst associate member state, Australia. Over the years, EMBL has become the agship of European molecular biology and has been continuously ranked as one of the top research institutes worldwide. EMBL is Europe’s only intergovernmental laboratory in the life sciences and as such its missions extend beyond performing cutting-edge research in molecular biology. It also oers services to Euro- pean scientists, most notably in the areas of bioinformatics and structural biology, provides advanced training to researchers at all levels, develops new technologies and instrumentation, and actively engages in technology transfer for the benet of scientists and society.
    [Show full text]
  • Spliceosomal Usnrnp Biogenesis, Structure and Function Cindy L Will* and Reinhard Lührmann†
    290 Spliceosomal UsnRNP biogenesis, structure and function Cindy L Will* and Reinhard Lührmann† Significant advances have been made in elucidating the for each of the two reaction steps. Components of the biogenesis pathway and three-dimensional structure of the UsnRNPs also appear to catalyze the two transesterifi- UsnRNPs, the building blocks of the spliceosome. U2 and cation reactions leading to excision of the intron and U4/U6•U5 tri-snRNPs functionally associate with the pre-mRNA ligation of the 5′ and 3′ exons. Here we describe recent at an earlier stage of spliceosome assembly than previously advances in our understanding of snRNP biogenesis, thought, and additional evidence supporting UsnRNA-mediated structure and function, focusing primarily on the major catalysis of pre-mRNA splicing has been presented. spliceosomal UsnRNPs from higher eukaryotes. Addresses Identification of a novel UsnRNA export factor Max Planck Institute of Biophysical Chemistry, Department of Cellular UsnRNP biogenesis is a complex process, many aspects of Biochemistry, Am Fassberg 11, 37077 Göttingen, Germany. which remain poorly understood. Although less is known *e-mail: [email protected] about the maturation process of the minor U11, U12 and †e-mail: [email protected] U4atac UsnRNPs, it is assumed that they follow a pathway Current Opinion in Cell Biology 2001, 13:290–301 similar to that described below for the major UsnRNPs 0955-0674/01/$ — see front matter (see Figure 1). The UsnRNAs, with the exception of U6 © 2001 Elsevier Science Ltd. All rights reserved. and U6atac (see below), are transcribed by RNA polymerase II as snRNA precursors that contain additional Abbreviations ′ CBC cap-binding complex 3 nucleotides and acquire a monomethylated, m7GpppG NLS nuclear localization signal (m7G) cap structure.
    [Show full text]
  • Curriculum Vitae Professor Dr. Iain W. Mattaj
    Curriculum Vitae Professor Dr. Iain W. Mattaj Name: Iain William Mattaj Born: 5 October 1952 Academic and Professional Career since 2005 Director General, European Molecular Biology Laboratory (EMBL) 1999 ‐ 2005 Scientific Director, European Molecular Biology Laboratory (EMBL) 1990 ‐ 2005 Programme Coordinator, Gene Expression Programme (EMBL) 1985 ‐ 1990 Group Leader at EMBL 1982 – 1985 Postdoctoral Research at the Biocenter, University of Basel with Dr. Eddy De Robertis 1979 ‐ 1982 Postdoctoral research at the Friedrich‐Miescher‐Institute, Basel, with Dr. Jean‐Pierre Jost 1978 ‐ 1979 Postdoctoral research at the University of Leeds, Dept. of Genetics, UK 1974 ‐ 1978 Postgraduate studies at the University of Leeds, Dept. of Genetics, UK with Dr. John Wootton 1970 ‐ 1974 Undergraduate studies at the University of Edinburgh, Scotland Functions in Scientific Societies and Committees 2010 ‐ 2011 FET (Future and Emerging Technologies) Flagships Science Coordination Group, Brussels since 2010 EMBO Scientific Publications Advisory Board 2009 ‐ 2010 Chair of the European Intergovernmental Scientific Research Organisation forum (EIROforum) since 2008 Chair of the Scientific Advisory Board of the DKFZ – ZMBH Alliance Nationale Akademie der Wissenschaften Leopoldina www.leopoldina.org 1 since 2008 Chair of the Advisory Board for the Wellcome Trust Centre for Gene Regulation and Expression, Dundee, Scotland 2007 ‐ 2010 Member of the Scientific Planning Committee, UK‐Centre for Medical Research and Innovation since 2007 Member, and from 2010 Chair,
    [Show full text]
  • Research at a Glance 2011
    European Molecular Biology Laboratory Research at a Glance 2011 European Molecular Biology Laboratory Research at a Glance 2011 Research at a Glance 2011 Contents 4 Foreword by Iain Mattaj, EMBL Director General 5 EMBL Heidelberg, Germany 6 Cell Biology and Biophysics Unit 17 Developmental Biology Unit 26 Genome Biology Unit 35 Structural and Computational Biology Unit 48 Directors’ Research 52 Core Facilities 61 EMBL-EBI, Hinxton, UK European Bioinformatics Institute 89 EMBL Grenoble, France Structural Biology 100 EMBL Hamburg, Germany Structural Biology 109 EMBL Monterotondo, Italy Mouse Biology 116 Index Foreword by EMBL‘s Director General EMBL – Europe’s leading laboratory for basic research in molecular biology The vision of the nations which founded the European Molecular Biology Laboratory was to create a centre of excellence where Europe’s best brains would come together to conduct basic research in molecular biology. During the past three decades, EMBL has grown and developed substantially, and its member states now number twenty-one, including the first associate member state, Australia. Over the years, EMBL has become the flagship of European molecular biology and has been continuously ranked as one of the top research institutes worldwide. EMBL is Europe’s only intergovernmental laboratory in the life sciences and as such its missions extend be- yond performing cutting-edge research in molecular biology. It also offers services to European scientists, most notably in the areas of bioinformatics and structural biology, provides advanced training to researchers at all levels, develops new technologies and instrumentation and actively engages in technology transfer for the ben- efit of scientists and society.
    [Show full text]
  • Univ.-Prof. Dr. Rer. Nat. Wolfram Antonin Institute of Biochemistry and Molecular Cell Biology
    Univ.-Prof. Dr. rer. nat. Wolfram Antonin Institute of Biochemistry and Molecular Cell Biology Personal Data Name: Univ.-Prof. Dr. rer. nat. Wolfram Antonin Address: Institute of Biochemistry and Molecular Cell Biology RWTH Aachen University Pauwelsstrasse 30 D-52074 Aachen Date and place of birth: September 26, 1972 in Bad Nauheim, Germany Academic Qualification 2017 W3 Professor for Biochemistry, RWTH Aachen University 2013 Habilitation in Cell Biology at the Eberhard Karls University Tübingen, 2001 Doctor of Natural Sciences, University of Hannover; grade: summa cum laude 1994 Diploma in Biochemistry, University of Hannover; grade: sehr gut Professional Career Since 2017 W3 Professor for Biochemistry and head of the Institute of Biochemistry and Molecular Cell Biology, RWTH Aachen University 2006-2017 Independent Max Planck research group leader at the Friedrich Miescher Laboratory of the Max Planck Society (W2, associate professor level, Oct 2015-Jan 2017 as an Heisenberg fellow) in Tübingen 2005-2006 Staff scientist at the European Molecular Biological Laboratory (EMBL) in Heidelberg 2002-2005 Postdoctoral fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg in the group of Dr. Iain Mattaj 2001 Research associate at the Max Planck Institute for Biophysical Chemistry in Göttingen in the group of Prof. Reinhard Jahn 1997-2001 PhD student at the Max Planck Institute for Biophysical Chemistry in Göttingen in the group of Prof. Reinhard Jahn 1992-1997 Undergraduate student in Biochemistry, University of Hannover Awards
    [Show full text]
  • Press Release for IMMEDIATE RELEASE
    European Molecular Biology Laboratory (EMBL) Europäisches Laboratorium für Molekularbiologie EMBL Laboratoire Européen de Biologie Moléculaire Office of Information and Public Affairs EMBL Meyerhofstr. 1 D-69117 Heidelberg, Germany Tel: +49 - 6221 - 3870 email: [email protected] Press Release FOR IMMEDIATE RELEASE A formula for multiplying by two EMBL researchers identify a key mechanism in cell division Source article: Ran Induces Spindle Assembly by Reversing the Inhibitory Effect of Importin on TPX2 Activity Authors: Oliver J. Gruss, Rafael E. Carazo-Salas, Christoph A. Schatz, Giulia Guarguaglini, Jürgen Kast, Matthias Wilm, Nathalie Le Bot, Isabelle Vernos, Eric Karsenti, and Iain W. Mattaj Cell, Vol. 104, 83–93, January, 2001, Copyright © 2001 by Cell Press Scientific contact: Iain W. Mattaj, 49 6221 387 393 (phone), 49 6221 387 518 (fax), [email protected] Note: Copyright for the text and images from this press release belong to the EMBL except where otherwise noted. They may be freely used and further distributed in if proper attribution to authors and photographers are made. Photographs may only be used in connection to the publication of this story. High-resolution copies of the images can be downloaded from the EMBL web site at: www.embl-heidelberg.de/ExternalInfo/oipa EMBL Press Release - Jan. 12, 2001 A formula EMBL researchers identify a for multiplying key mechanism by two in cell division Christoph Schatz and Oliver Gruss photo: Doug Young here are roughly 100 trillion (100,000,000,000,000) cells in each of our bodies, and every one was Tproduced by cell division: the initial fertilized egg split into two daughter cells and then the numbers grew, two by two.
    [Show full text]
  • Biblio.Ugent.Be
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Ghent University Academic Bibliography biblio.ugent.be The UGent Institutional Repository is the electronic archiving and dissemination platform for all UGent research publications. Ghent University has implemented a mandate stipulating that all academic publications of UGent researchers should be deposited and archived in this repository. Except for items where current copyright restrictions apply, these papers are available in Open Access. This item is the archived peer-reviewed author-version of: Nuclear inclusion of non-targeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles Authors: Symens N., Walczak R., Demeester J., Mattaj I., De Smedt S.C., Remaut K. In: Molecular Pharmaceutics, 2011, 8(5), 1757-1766 Optional: link to the article To refer to or to cite this work, please use the citation to the published version: Authors (year). Title. journal Volume(Issue) page-page. Doi 10.1021/mp200120v Nuclear inclusion of non-targeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles Nathalie Symens1*, Rudolf Wa l czak2, Joseph Demeester1, Iain Mattaj2, Stefaan C. De Smedt1and Katrien Remaut1** 1. Laboratory of General Biochemistry and Physical Pharmacy (Ghent Research Group on Nanomedicines), Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium. 2. Directors’ Research, Mattaj Group, European Molecular Biology Laboratory, Meyerhofstraβe 1, 69117 Heidelberg, Germany. *[email protected] **Corresponding author: [email protected], phone number +32 9 264 80 47; fax number +32 9 264 81 89 ABSTRACT. The nuclear membrane is one of the major cellular barriers in the delivery of plasmid DNA (pDNA).
    [Show full text]
  • Exportin 5 Is a Rangtp-Dependent Dsrna-Binding Protein That Mediates Nuclear Export of Pre-Mirnas
    Downloaded from rnajournal.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press REPORT Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs MARKUS T. BOHNSACK,1,3 KEVIN CZAPLINSKI,2,3 and DIRK GO¨ RLICH1 1Zentrum für Molekulare Biologie, Heidelberg, Germany 2European Molecular Biology Laboratory, Heidelberg, Germany ABSTRACT microRNAs (miRNAs) are widespread among eukaryotes, and studies in several systems have revealed that miRNAs can regulate expression of specific genes. Primary miRNA transcripts are initially processed to ≈70-nucleotide (nt) stem–loop structures (pre-miRNAs), exported to the cytoplasm, further processed to yield ≈22-nt dsRNAs, and finally incorporated into ribonucleo- protein particles, which are thought to be the active species. Here we study nuclear export of pre-miRNAs and show that the process is saturable and thus carrier-mediated. Export is sensitive to depletion of nuclear RanGTP and, according to this criterion, mediated by a RanGTP-dependent exportin. An unbiased affinity chromatography approach with immobilized pre-miRNAs identified exportin 5 as the pre-miRNA-specific export carrier. We have cloned exportin 5 from Xenopus and demonstrate that antibodies raised against the Xenopus receptor specifically block pre-miRNA export from nuclei of Xenopus oocytes. We further show that exportin 5 interacts with double-stranded RNA in a sequence-independent manner. Keywords: miRNA; tRNA; nuclear transport; exportin; translation regulation; silencing INTRODUCTION Most nuclear protein transport pathways are mediated by importins or exportins, which are all (at least distantly) The nuclear envelope (NE) separates eukaryotic cells into a related to importin ␤ (Imp␤;for reviews, see Mattaj and nuclear and a cytoplasmic compartment and thereby neces- Englmeier 1998;Wozniak et al.
    [Show full text]
  • Report of the Trustees (Incorporating Strategic Report) and Financial Statements for the Period 3 October 2012 to 31 December 2013
    REGISTERED COMPANY NUMBER: 08239097 (England and Wales) REGISTERED CHARITY NUMBER: 1149638 Report of the Trustees (incorporating Strategic Report) and Financial Statements for the Period 3 October 2012 to 31 December 2013 for THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES Hill Wooldridge & Co. Limited Statutory Auditor & Chartered Accountants 107 Hindes Road Harrow Middlesex HA1 1RU THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES Contents of the Financial Statements for the Period 3 October 2012 to 31 December 2013 Page Report of the Trustees incorporating Strategic Report 1 to 13 Report of the Independent Auditors 14 to 15 Statement of Financial Activities 16 Balance Sheet 17 Cash Flow Statement 18 Notes to the Cash Flow Statement 19 Notes to the Financial Statements 20 to 28 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES Report of the Trustees incorporating Strategic Report for the Period 3 October 2012 to 31 December 2013 The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report, which incorporates the strategic report, with the financial statements of the charity for the period 3 October 2012 to 31 December 2013. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by Charities' issued in March 2005. REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number 08239097 (England and Wales) Registered Charity number 1149638 Registered office 98 Regent Street Cambridge Cambridgeshire CB2 1DP Trustees I Pecht
    [Show full text]
  • Scientific Programme 2001 - 2005
    EMBL Scientific Programme 2001 - 2005 Preface Every five years, the EMBL submits to its governing Council pro- posals for the Scientific Programme to be pursued in the following quinquennium, and for the associated budgetary ceiling (Indicative Scheme). Decisions on these two items are the only ones for which the EMBL Council must achieve unanimity of the member states that are present and voting. EMBL considers these decisions very important not only for the obvious pragmatic reasons, but also because they represent the blueprint according to which we will operate over five years - a very long time for molecular biology! Consistent with the princi- ples that I set as the foundation of my tenure when I was elected Director-General in 1993 (the triad “excellence - cooperation - inclusiveness”), I take the responsibility of planning very seri- ously and conduct it as a collaborative exercise, both within the Laboratory and in the member states. This draft Scientific Programme proposal was formulated within the EMBL in intensive discussions and drafting over eight months (late February to mid-October, 1999). We began with an exciting two-day retreat of all the group leaders and team leaders, during which the broad directions of our plan began to emerge. Subsequent discussions engaged mostly the heads of Units and Senior Scientists. As our plans became clearer, we exposed them to valuable critique by panels of experts that we invited to consul- tations in Heidelberg for this purpose - all the members of our standing scientific Advisory Committee (SAC), and an approxi- mately equal number of other leading scientists, with a significant contingent from the US to give us a truly external perspective.
    [Show full text]